Nuvo Receives Approvable Letter From U.S. FDA For Pennsaid

... Nuvo Research Inc. (TSX:NRI) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Pennsaid(R) (1.5% w/w diclofenac sodium solution), a topical non-steroidal anti-inflammatory (NSAID) developed by Nuvo for use as a treatment of osteoarthritis (OA) of the knee. [click link for full article] ...